Home Cart Sign in  
Chemical Structure| 871361-88-5 Chemical Structure| 871361-88-5

Structure of SC66
CAS No.: 871361-88-5

Chemical Structure| 871361-88-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SC66 is an allosteric and dual-inhibitory-function inhibitor of Akt which can lead to a reduction in total and phospho-AKT levels.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SC66

CAS No. :871361-88-5
Formula : C18H16N2O
M.W : 276.33
SMILES Code : O=C1/C(CCC/C1=C\C2=CC=NC=C2)=C/C3=CC=NC=C3
MDL No. :MFCD05025493
InChI Key :CYVVJSKZRBZHAV-UNZYHPAISA-N
Pubchem ID :6018993

Safety of SC66

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of SC66

PI3K-AKT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
ES-2/CP 0-22 μM 48 h SC66 inhibited phosphorylation of Akt and its downstream effectors 4EBP1 and p70S6 kinase, and attenuated expression of TWIST1 and Mcl-1. Cell Death Dis. 2019 Apr 11;10(4):322.
ES-2 0-22 μM 48 h SC66 inhibited phosphorylation of Akt and its downstream effectors 4EBP1 and p70S6 kinase, and attenuated expression of TWIST1 and Mcl-1. Cell Death Dis. 2019 Apr 11;10(4):322.
OVCAR-8 0-22 μM 48 h SC66 inhibited phosphorylation of Akt and its downstream effectors 4EBP1 and p70S6 kinase, and attenuated expression of TWIST1 and Mcl-1. Cell Death Dis. 2019 Apr 11;10(4):322.
OVCAR-4 0-22 μM 48 h SC66 inhibited phosphorylation of Akt and its downstream effectors 4EBP1 and p70S6 kinase, and attenuated expression of TWIST1 and Mcl-1. Cell Death Dis. 2019 Apr 11;10(4):322.
OVCAR-3 0-22 μM 48 h SC66 inhibited phosphorylation of Akt and its downstream effectors 4EBP1 and p70S6 kinase, and attenuated expression of TWIST1 and Mcl-1. Cell Death Dis. 2019 Apr 11;10(4):322.
HAC-2 0-22 μM 48 h SC66 inhibited phosphorylation of Akt and its downstream effectors 4EBP1 and p70S6 kinase, and attenuated expression of TWIST1 and Mcl-1. Cell Death Dis. 2019 Apr 11;10(4):322.
A2780CP70 0-22 μM 48 h SC66 inhibited phosphorylation of Akt and its downstream effectors 4EBP1 and p70S6 kinase, and attenuated expression of TWIST1 and Mcl-1. Cell Death Dis. 2019 Apr 11;10(4):322.
A2780 0-22 μM 48 h SC66 inhibited phosphorylation of Akt and its downstream effectors 4EBP1 and p70S6 kinase, and attenuated expression of TWIST1 and Mcl-1. Cell Death Dis. 2019 Apr 11;10(4):322.
5637 cells 0, 2, 4, 6, 8, 10, 12, 14, 16, 18 μM 24 h SC66 significantly inhibited the proliferation of 5637 cells, and the degree of inhibition was positively correlated with the drug concentration. J Cell Mol Med. 2021 Nov;25(22):10684-10697.
T24 cells 0, 2, 4, 6, 8, 10, 12, 14, 16, 18 μM 24 h SC66 significantly inhibited the proliferation of T24 cells, and the degree of inhibition was positively correlated with the drug concentration. J Cell Mol Med. 2021 Nov;25(22):10684-10697.
HeLa cells 4 μg/mL 1 hour SC66 significantly reduced the phosphorylation level of Akt Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6486-91.
HEK293T cells 1, 2, 4 μg/mL 1 hour SC66 significantly reduced the phosphorylation level of both Akt and its targets Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6486-91.
Primary human RCC cells 3 μM 24 h SC66 significantly reduced the viability, proliferation, and migration of primary human RCC cells. Cell Death Dis. 2020 May 11;11(5):353.
A498 cells 3 μM 48-72 h SC66 decreased cell viability and proliferation, and inhibited A498 cell migration and invasion. Cell Death Dis. 2020 May 11;11(5):353.
786-O cells 1-30 μM 48-96 h SC66 dose-dependently reduced the viability of 786-O cells and significantly decreased the number of viable 786-O cell colonies in soft agar. Cell Death Dis. 2020 May 11;11(5):353.
HCT-116 WT, HCT-116 p53−/−, DLD1 2 μg/ml 24 h SC66 significantly inhibited the proliferation of HCT-116 WT, HCT-116 p53−/−, and DLD1 cells, and p53 was dispensable in this process. Cancer Cell Int. 2019 May 9;19:124.
HCT-116 0.5–4 μg/ml 24 h SC66 significantly inhibited the proliferation of HCT-116 cells in a dose-dependent manner. Cancer Cell Int. 2019 May 9;19:124.
U251 cells 0, 5, 10, 15, 20, 25, 30 μM 24 h SC66 inhibited U251 cell proliferation with an IC50 value of 12 umol/L Front Pharmacol. 2020 Jul 31;11:1102.
U87 cells 0, 5, 10, 15, 20, 25, 30 μM 24 h SC66 inhibited U87 cell proliferation with an IC50 value of 10 umol/L Front Pharmacol. 2020 Jul 31;11:1102.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NOD-SCID mice Ovarian cancer xenograft model Intraperitoneal injection 5 mg/kg and 15 mg/kg Once per day for 30 days SC66 treatment significantly inhibited tumor formation and enhanced the therapeutic efficacy of cisplatin. Cell Death Dis. 2019 Apr 11;10(4):322.
Balb/c nude mice T24 tumor model Intraperitoneal injection 20 mg/kg Every 2 days for 4 weeks SC66 significantly reduced the weight and volume of T24 tumors in nude mice, and the combination with cisplatin showed better inhibition. J Cell Mol Med. 2021 Nov;25(22):10684-10697.
Mice HEK293T cell xenograft model Intraperitoneal injection 15, 30 mg/kg Twice per week for 21 days SC66 significantly inhibited tumor growth Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6486-91.
SCID mice 786-O xenograft model Oral 10-25 mg/kg Once daily for 24 days SC66 significantly inhibited the growth of 786-O xenograft tumors, and AKT-mTOR inhibition, SphK1 inhibition, ceramide accumulation, and JNK activation were detected in SC66-treated 786-O xenograft tumors. Cell Death Dis. 2020 May 11;11(5):353.
Nude mice HCT-116 WT xenograft model Intraperitoneal injection 25 mg/kg Every 3 days for 15 days SC66 significantly inhibited the growth of HCT-116 WT xenograft tumors, with an inhibition rate of about 65%. Cancer Cell Int. 2019 May 9;19:124.
Nude mice U87 xenograft tumor model Intraperitoneal injection 25 mg/kg Every 3 days for 6 times SC66 significantly suppressed tumor growth, with tumor weights and volume notably smaller than the control group Front Pharmacol. 2020 Jul 31;11:1102.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.62mL

0.72mL

0.36mL

18.09mL

3.62mL

1.81mL

36.19mL

7.24mL

3.62mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories